TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ANIX

Anixa Biosciences Inc

Healthcare · Biotechnology

2.80$ +0.0% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow ANIX
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-64.9% 14.7% -1,127.2% -1,047.4% -384.1% -1,896.6% – -964.5% -0.3% -2,956.7% – –
8.6% 3.6% 119.5% 101.7% 30.9% 186.5% – 11.7% 0.0% 21.9% – –
85.9% 28.9% 291.2% 461.6% 771.0% 2,206.1% – 1,465.4% 0.2% 2,105.7% – –
154.5% 29.7% 301.6% 57.2% 566.3% 1,591.9% – 1,538.9% 0.3% – – –
-26.9% -9.5% -53.5% 112.6% 6.1% 191.4% – 15.2% 0.0% -504.8% – –
0.2% 0.6% 48.8% 8.3% 3.5% 70.2% – 0.0% 0.0% 0.0% – –
-68.4% 0.5% 501.2% -754.5% 131.4% -210.2% – -765.0% -0.4% -2,667.6% – –
0.4% 0.0% – 0.0% 0.0% – – – – – – –
0.4% -4.8% 3.9% -137.9% 227.3% 2,275.4% – – 0.0% 0.0% – –
95.4% -32.4% -1,000.0% -827.6% – – – – – – – –
200.4% -4.3% -0.9% 2,036.7% 227.3% 2,281.0% – 6,165.2% 0.0% 174.3% – –
67.2% 10.9% -627.0% 234.8% -25.5% 174.3% – 4,435.7% -0.7% -5,450.0% – –
-65.1% 14.1% -1,176.1% -1,055.7% -387.6% -1,966.8% – -964.5% -0.3% -2,956.7% – –

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?